The PathMaker program is a stepping stone for students interested in a career in health sciences or STEM with backgrounds underrepresented in the biomedical workforce.
Cancer Research Posts
Study of Utah Lung Cancer Patients Finds Those Who Never Smoked May Have Genetic Predisposition for Cancer
Despite Utah's low smoking rate, lung cancer remains the leading cause of cancer death in Utah. In addition, lung cancer in people who have used tobacco and people who have never smoked behaves differently. Researchers at Huntsman Cancer Institute wanted to know why.
Huntsman Cancer Institute established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Howard Colman, MD, PhD is a physician-scientist specializing in the treatment of brain tumors and the diagnosis and management of neurologic complications of cancer.
The state of Huntsman Cancer Institute is strong and focused, according to CEO Mary Beckerle, PhD. The annual presentation to faculty, staff, and students is a chance for Dr. Beckerle to reflect on accomplishments of the prior year and outline priorities for the future.
Huntsman Cancer Institute established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Adam Cohen, MD, MS, was recently honored with a Huntsman Translational Scholar award. He is a researcher and physician, specializing in neuro-oncology and breast oncology.
Are you thinking about taking part in a clinical trial? Read these five frequently asked questions about clinical trials.
“Delivering Discoveries: Expanding the Reach of Precision Medicine,” was the theme of the American Society of Clinical Oncology (ASCO) 2018 annual meeting held June 1-5, 2018 in Chicago. One of the largest scientific conferences in the world, the meeting brings together nearly 40,000 attendees and features thousands of studies about new ways to prevent, detect, and treat cancer.
It is patients like you, your loved ones, and Dr. Gertz's parents who keep us motivated and excited to find ways to help in the fight against this terrible disease. We appreciate everything you do as patients—like donating samples and participating in clinical trials—and we want you to know that we are doing everything we can to help patients with breast and uterine cancer.
HCI established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Deborah Stephens, DO, was recently honored with a Huntsman Translational Scholar award. She is the physician leader of the Hematology Clinical Trials at Huntsman Cancer Institute and is also an Assistant Professor in the Division of Hematology and Hematologic Malignancies at the University of Utah.
On May 16, 2018, HCI hosted a NASA astronaut and a team from the Center for the Advancement of Science in Space to discuss the opportunity of researching cancer in space.
HCI established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Theresa Werner, MD, was recently honored with a Huntsman Translational Scholar award. She is the medical director of Clinical Trials and treats patients with gynecologic cancers.
Huntsman Cancer Institute Opens Center for HOPE and is Awarded $9.7 Million to Improve Health Among Underserved Populations
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) today announced the opening of the Cancer Population Sciences and Huntsman Center for Health Outcomes and Population Equity (HOPE), a new research and clinical space dedicated to preventing cancer and improving health among underserved populations and improving outcomes in cancer patients. The center recently received $9.7 million from the Patient-Centered Outcomes Research Institute (PCORI) to fund a clinical trial researching new and effective approaches to reduce tobacco use.
“Driving Innovative Cancer Science to Patient Care” was the theme of the American Association for Cancer Research (AACR) annual meeting, which took place April 14-18 in Chicago. Huntsman Cancer Institute (HCI) faculty and staff joined almost 22,000 other scientists, physicians, and patient advocates from around the world to share the latest findings in translational, clinical, and prevention-focused cancer research.
HCI established The Society of Huntsman Translational Scholars to recognize excellence in the discipline of translational science. Robert Andtbacka, MD, was recently honored with a Huntsman Translational Scholar award and will also lead the group for the coming year.
The PathMaker Cancer Research Program is for high school and undergraduate students with backgrounds underrepresented in the biomedical workforce. Under the mentorship of an HCI scientist, PathMaker scholars conduct research and build a foundation for careers in health professions and biomedical research.
The Young Adult Cancer Caregiver study is currently recruiting participants. The study will look at how social media may help or hinder young adults who take care of a cancer patient.
This infographic highlights a few of Huntsman Cancer Institute's accomplishments in 2017.
Advancing discoveries made in the lab to medical treatments that can be used in patient care is complex and time-consuming. Commonly called clinical translation, this process can be thought of much like translating something from one language to another.
Huntsman Cancer Institute began in 1995 with an empty lot and a dream full of promise. Twenty-two years later, HCI opened a major expansion that doubled its research capacity.
Targeted therapy in cancer treatment is often called personalized or precision medicine, according to the National Institutes of Health. Targeted therapies are designed to be more effective and less harmful than other approaches because the drugs are specially designed to meet the individual characteristics of each patient.